Why Is Replimune Group (REPL) Stock Down -63.24% Today?
Key Takeaways
- Replimune Group (REPL) shares collapsed approximately 63.24% in premarket trading on Monday, April 13, 2026, falling from a Friday close of $4.76 to around $1.75.
- The primary catalyst is the FDA's second consecutive Complete Response Letter (CRL) issued April 10, 2026, rejecting the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma.
- Replimune's CEO confirmed the company will cut its workforce and substantially scale back U.S. manufacturing operations as a direct consequence.
- Management stated that without timely accelerated FDA approval, continued development of RP1 is not viable — effectively placing the company's lead asset in jeopardy.
- A wave of analyst downgrades swept across Wall Street over the weekend, with price targets slashed to between $1 and $4.
- Investors are now closely watching whether Replimune will pursue another regulatory submission, seek a Type A meeting with the FDA, or pivot to other pipeline assets.
Opening Summary
Replimune Group, Inc. (REPL) is a Woburn, Massachusetts-based clinical-stage biotechnology company that develops oncolytic immunotherapies — treatments that use genetically modified viruses to selectively attack cancer cells and stimulate the immune system. Shares of REPL entered Monday's premarket session in freefall, trading near $1.75 as of the early hours of April 13, 2026, compared to Friday's closing price of $4.76 — a decline of approximately 63.24%. The immediate trigger was the U.S. Food and Drug Administration's decision, disclosed after Friday's market close, to again refuse approval of Replimune's lead drug candidate RP1 for the treatment of advanced melanoma, marking the second such rejection in less than a year.
FDA's Second Complete Response Letter
On April 10, 2026 — the PDUFA target action date — the FDA issued a second Complete Response Letter for Replimune's BLA seeking accelerated approval of RP1 in combination with Bristol Myers Squibb's nivolumab (Opdivo) for patients with advanced melanoma who had progressed on anti-PD-1-based therapy. The FDA's reviewers from the Office of Therapeutic Products and the Oncology Center of Excellence unanimously determined that the data presented were "insufficient to conclude substantial evidence of effectiveness." The agency maintained its earlier objection that the pivotal IGNYTE trial — a single-arm study showing a 34% response rate and a median duration of response of 24.8 months — does not qualify as an adequate and well-controlled clinical investigation, and that the heterogeneity of the patient population makes results difficult to interpret.
Replimune resubmitted the application in October 2025 following the first rejection in July 2025, including new analyses on RP1's mechanism of action and additional data. However, the FDA affirmed its prior position, expanding upon original concerns rather than softening them. CEO Sushil Patel expressed surprise at the outcome, noting the issues outlined in the CRL had not been raised during mid- and late-cycle reviews, and that the company believed it had aligned with the FDA on confirmatory study design.
Operational Fallout: Layoffs and Manufacturing Cutbacks
The consequences of the second rejection extend well beyond the stock price. CEO Sushil Patel announced that Replimune is compelled to reduce its workforce and significantly downsize its U.S. manufacturing operations as a direct result of the FDA's decision. The company had previously warned in a February 2026 SEC filing that a second CRL could lead management to determine that RP1's development is "no longer viable." Without timely accelerated approval, Replimune has stated publicly that advancing RP1 for advanced cancer patients with few treatment alternatives will not be feasible.
Cascade of Analyst Downgrades
The FDA's decision triggered an unusually broad and severe round of analyst downgrades over the weekend, compounding the selling pressure entering Monday's premarket:
- Jefferies downgraded REPL to Hold from Buy and slashed its price target to $2 from $13, calling the road ahead "tough."
- JPMorgan downgraded to Underweight from Neutral, withdrawing its prior $10 price target entirely, and warned shares would likely trade in the low single digits amid "greater uncertainty on the prospects for RP1."
- BMO Capital Markets downgraded to Underperform with a $1 price target, down from $11.
- Cantor Fitzgerald cut to Neutral from Overweight, noting the FDA reaffirmed and expanded upon its prior concerns, rather than offering more regulatory flexibility.
- Piper Sandler lowered its rating to Neutral and reduced its price target to $4 from $14.
- H.C. Wainwright issued a double downgrade to Sell from Buy, citing the need to await clarity on any regulatory path forward.
Market Context and Trading Activity
The premarket decline in REPL was accompanied by sharply elevated trading volume relative to normal pre-market activity, consistent with forced institutional repositioning following the Friday-night announcement. The stock had already lost approximately 19–20% during regular Friday trading as the CRL news broke, and the after-hours and premarket sessions extended the selloff dramatically as analysts and funds absorbed the full implications overnight. A NASDAQ volatility trading halt was triggered during Friday's session as prices moved sharply.
The broader biotech sector, tracked by the SPDR S&P Biotech ETF (XBI), was not under comparable pressure, underscoring that this was a company-specific and binary-event-driven move rather than a systemic sector rotation. The collapse also reflects the market pricing in an existential threat to Replimune's core pipeline, given that RP1 represented the company's singular near-term commercial opportunity with potential peak annual sales of up to $800 million according to prior analyst estimates.
Trending AI Robots
For traders navigating volatile, catalyst-driven events like the REPL FDA-driven collapse, Tickeron's Trending AI Robots page offers a curated view of the platform's best-performing automated trading strategies under current market conditions. Tickeron operates hundreds of AI-powered trading bots covering thousands of tickers across equities, ETFs, and other instruments — but only the top performers, ranked by real-time metrics including return, win rate, and risk-adjusted performance, are featured in this dedicated section. Bots vary by strategy type (momentum, mean-reversion, breakout), timeframe (intraday to swing), and the symbols they trade, giving investors a range of approaches to explore. Explore the Trending AI Robots page to identify AI-driven strategies aligned with your trading style and current market environment.
What Comes Next for REPL
Replimune has indicated it plans to request a Type A meeting with the FDA — typically granted within 30 days — to understand whether any regulatory path to accelerated approval for RP1 remains open. The company is also conducting the Phase 3 IGNYTE-3 confirmatory trial, and earlier data in acral melanoma may provide an alternative submission basis. However, with management explicitly warning that RP1 development is not viable without accelerated approval, the timeline to any potential resubmission remains deeply uncertain. Investors will be watching for announcements regarding the Type A meeting outcome, any strategic partnership or licensing discussions, the scope of the workforce reduction, and whether Replimune revisits early-stage pipeline assets including RP2 and RP3 as potential go-forward programs. Cash runway and financing capacity will also be key concerns given the company's pre-revenue clinical-stage status and the sharp reduction in market capitalization.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
REPL in upward trend: 10-day moving average moved above 50-day moving average on May 26, 2026
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on May 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on REPL as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for REPL just turned positive on June 17, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
REPL moved above its 50-day moving average on May 29, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 195 cases where REPL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
REPL broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.384) is normal, around the industry mean (20.977). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). REPL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (366.956).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement